Hippocampal DVR was strongly correlated with the Beck’s Depression Inventory score in patients with MS.
Estriol, combined with glatiramer acetate, was associated with a reduced MS relapse rate.
Long thought to be driven by T cells, a mouse model indicates a troublesome role for macrophages in MS.
Early detection of JCV variants may help prevent the development of severe cases of PML.
OCT would also be useful as an outcome in investigative clinical trials.
Higher levels of vitamin D were associated with decreased disease activity in people with RRMS.
The drug may be a good option for those with aggressive and treatment-resistant MS.
The electronic injection system reminds patients of when their next injection is due to occur.
Smoking after MS diagnosis appears to affect the rate of conversion to secondary-progressive MS.
Mental visual imagery training can improve autobiographical memory and episodic future thinking in MS.
Breastfeeding exclusively for at least two months was associated with a lower risk of MS relapse.
This is potentially the fourth possible case of PML in patients using Gilenya.
The MS drug has been definitively linked to at least one case of PML.
A new antibody that inhibits MCAM activity may be the first treatment that can halt the progression of multiple sclerosis.
The approval comes after Teva Pharmaceuticals filed eight citizen petitions and fought several court battles to protect Copaxone.
The trial will evaluate the use of memory and external aids, like cell phones, for memory recall in multiple sclerosis.
Teva is in the process of converting patients to a new, patent-protected version of Copaxone.
There is currently no approved treatments for RMS that have been shown to change the course of the disease.
PML infections have been reported in other drugs used to treat multiple sclerosis.